Inhibition of RAAS—When is it too much?
Deactivation of the renin-angiotensin-aldosterone system (RAAS) is clearly beneficial in patients with recent myocardial infarction and chronic heart failure. Most of the experience with deactivation of the RAAS has been collected in placebo-controlled randomized trials of angiotensinconverting enzyme inhibition (ACEI). The hypothesis that angiotensin receptor blockade may be a better approach to deactivate the RAAS has not survived the test of time. Despite the extensive experience with ACEI and aldosterone receptor blockade in patients with recent myocardial infarction and chronic heart failure, several issues remain unanswered. These are addressed in this review.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 5.Pfeffer MA, Braunwald E, Moye LA, et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992, 327:669–677.PubMedCrossRefGoogle Scholar
- 6.Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993, 342:821–828.Google Scholar
- 13.Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. The NETWORK Investigators. Eur Heart J 1998, 19:481–489.Google Scholar
- 14.Packer M, Poole-Wilson PA, Armstrong PW, et al.: Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS study group. Circulation 1999, 100:2312–2318. This is the largest (with the greatest duration) of the studies that examine the issue of ACE inhibitor dosing. ATLAS provides convincing evidence that high-dose ACE inhibition is associated with a reduction in morbidity yet no significant mortality benefit.PubMedGoogle Scholar
- 18.Berger R, Stanek B, Hulsmann M, et al.: Delayed effects of one-year treatment with low-dose as compared with highdose enalapril on morbidity and mortality of patients with severe heart failure. J Clin Bas Cardiol 1998, 1:19–24.Google Scholar
- 23.McMurrayJ, Ostergran J, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensinconverting enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362:767–771. This recent study demonstrated a significant combined morbidity and mortality benefit with ACE inhibitor/ARB combination therapy in patients with relatively severe heart failure followed for more than 3 years.PubMedCrossRefGoogle Scholar
- 24.Pfeffer M, McMurray J, Velazquez E, et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893–1906. This large, recent study found no significant advantages of combination therapy in patients with MI and heart failure, and provides further evidence of comparable effects of ACE inhibitor and ARB therapy. A post hoc analysis revealed a significant reduction in hospitalizations in the valsartan-and-captopril group compared with the captopril group.PubMedCrossRefGoogle Scholar
- 42.Pitt B, Zannad F, Remme W, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709–717. This landmark trial demonstrated that the addition of aldosterone blockade to background therapy in patients with severe congestive heart failure leads to a significant reduction in all-cause mortality and morbidity.PubMedCrossRefGoogle Scholar
- 43.Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309–1321. The recent EPHESUS trial extends the use of aldosterone blockade to patients with LV dysfunction and signs of heart failure after MI. Although significant, the magnitude of morbidity and mortality benefit was less than in RALES.PubMedCrossRefGoogle Scholar
- 50.Shekelle P, Rich M, Morton S, et al.: Efficacy of angiotensinconverting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status. J Am Coll Cardiol 2003, 41:1529–1538. This meta-analysis provides evidence of ACE inhibitor benefit in several subgroups, except women with asymptomatic LV dysfunction. A pooled analysis revealed the same relative risk reduction with ACE inhibitor usage in black patients and white patients, although the reduction was not statistically significant in black patients.PubMedCrossRefGoogle Scholar